Skip to main content
GutCited

Bifidobacterium breve untuk Irritable Bowel Syndrome (IBS)

D

Limited data from small studies. Preliminary evidence for symptom improvement.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dbifidobacterium\u002Dbreve\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

D

Kesimpulan

Limited data from small studies. Preliminary evidence for symptom improvement.

Key Study Findings

Review
Compendium of Bifidobacterium-based probiotics: characteristics and therapeutic impact on human diseases.
Dose: None vs: None Outcome: None Efek: None None

Populasi: None

Other n=1098 8 weeks Open-label
A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of …
Dose: None vs: None (single-arm open-label) Outcome: Treatment success for abdominal pain and bloating Efek: 73% pain, 81.9% bloating success at T1 <0.001

Populasi: IBS patients from 52 Italian gastroenterologists

Randomized Controlled Trial n=61 8 weeks Double-blind
Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with …
Dose: None vs: Placebo Outcome: IBS-SSS symptom severity score change Efek: None None

Populasi: Patients with moderate-severe diarrhea-predominant IBS

Randomized Controlled Trial 4 weeks
Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group …
Dose: 2 g vs: Placebo Outcome: Constipation symptoms Efek: None P = 0.005

Populasi: IBS patients

Review
Postbiotics: A new member in the biotics family.
Dose: None vs: None Outcome: Clinical applications overview Efek: None None

Populasi: General population (review)

In Vitro
Bowel Inflammation and Nutrient Supplementation: Effects of a Fixed Combination of Probiotics, Vitamins, and Herbal …
Dose: None vs: None Outcome: Colitis severity Efek: None None

Populasi: Crohn's disease patients

Key Statistics

2

Studi

150

Peserta

Positive

D

Peringkat

Referenced Papers

Archivos argentinos de … 2024 3 sitasi
Journal of clinical … 2004 205 sitasi

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosis yang Umum Digunakan

general:
1-10 billion CFU/day
adultgisupport:
5-10 billion CFU/day
neonatalsupport:
1-5 billion CFU/day (as directed by pediatrician)

Batas atas: Well-tolerated up to 10 billion CFU/day in clinical trials

Dosis yang Diteliti dalam Penelitian

Dosis Durasi Efek N
None -- Mixed --
None 8 weeks Positive 1098
None 8 weeks Neutral 61
2 g 4 weeks Mixed --
None -- Positive --
None -- Positive --
Serum-derived bovine immunoglobulin (SBI) -- Positive --
None -- Positive --

Waktu terbaik diminum: Before meals or on empty stomach; for infants, mix with breast milk or formula

Safety & Side Effects

Efek Samping yang Dilaporkan

  • Mild gas during initial use
  • Occasional loose stools in infants (transient)
  • Rare abdominal discomfort
  • Very rare: bacteremia in immunocompromised individuals

Interaksi yang Diketahui

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Immunosuppressants (use with caution in immunocompromised patients)

Asupan atas yang dapat ditoleransi: Well-tolerated up to 10 billion CFU/day in clinical trials

Selalu konsultasikan dengan tenaga kesehatan Anda sebelum memulai suplemen apa pun.Selalu konsultasikan dengan penyedia layanan kesehatan Anda sebelum memulai suplemen apa pun.

Frequently Asked Questions

Does Bifidobacterium breve help with Irritable Bowel Syndrome (IBS)?
Based on 2 studies with 150 participants, there is preliminary evidence that needs more research that Bifidobacterium breve may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is D (Very Early Research).
How much Bifidobacterium breve should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bifidobacterium breve?
Reported side effects may include Mild gas during initial use, Occasional loose stools in infants (transient), Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bifidobacterium breve and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is positive.

Related Evidence

Penafian FDA: Pernyataan-pernyataan ini belum dievaluasi oleh Food and Drug Administration. Produk dan informasi di situs web ini tidak dimaksudkan untuk mendiagnosis, mengobati, menyembuhkan, atau mencegah penyakit apa pun. Peringkat bukti yang disajikan didasarkan pada analisis kami terhadap penelitian yang ditinjau sejawat dan tidak merupakan saran medis. Selalu konsultasikan dengan penyedia layanan kesehatan Anda sebelum memulai regimen suplemen apa pun.